Drug Trial Radar · NCT01163149
Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)
Last checked: Nov 20, 2026Latest source record: Mar 13, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Jun 2010
Primary completion
Jun 2016
Study completion Jun 2016
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 15, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 13 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial was conducted to study hypophosphatasia (HPP), a bone disorder caused by gene mutations or changes. These gene mutations cause low levels of an enzyme needed to harden bone. The purpose of this study was to test the safety and efficacy of two doses of the study drug called asfotase alfa as compared to a control group to see effects on adolescents and adults with HPP.
Conditions
- Hypophosphatasia
Interventions
asfotase alfaDrug
Cohort 1: Daily SC injections of 0.3 mg/kg asfotase alfa (total of 2.1 mg/kg/week)
asfotase alfaDrug
Cohort 2: Daily SC injections of 0.5 mg/kg Asfotase Alfa (3.5 mg/kg/week total)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 24 for Plasma Pyridoxal-5' Phosphate (PLP)Time frame: Baseline, Week 24
- Change From Baseline to Week 24 for Plasma Inorganic Pyrophosphate (PPi)Time frame: Baseline, Week 24
- Safety and Tolerability of Asfotase AlfaTime frame: Up to 288 weeks exposure to asfotase alfa
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Shriner's Hospital for Children
St Louis, Missouri
Duke University Medical Center
Durham, North Carolina
Health Sciences Centre Winnipeg, University of Manitoba
Winnipeg, Manitoba, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.